Bayer Strengthens Drug Discovery Platform with US$2 B Vividion Buyout
By Debadrita Paul
Pharma Deals Review: Vol 2021 Issue 9 (Table of Contents)
Published: 22 Sep-2021
DOI: 10.3833/pdr.v2021.i9.2637 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Bayer has completed the acquisition of Vividion, which uses its proprietary platform to address conventionally undruggable targets in the areas of immunology and oncology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS